Industry News

• Fremanezumab data in The Lancet demonstrate clinically meaningful reduction in migraines  Teva announced that results from the Phase IIIb FOCUS study, which examined fremanezumab versus placebo in adult migraine patients who previously experienced inadequate responses to two to four classes of preventive treatments, were published online ahead of print in The Lancet.
  August 21, 2019  
• Fear of rejection is transplant patient’s top concern  CareDx announced results of a national informational survey conducted with The American Association of Kidney Patients of kidney transplant recipients that assessed their key concerns about monitoring kidney health post-transplant. Fear of organ rejection was the number one health concern reported.
  August 21, 2019  
• NIH funds genetic counseling resource ahead of million-person sequencing effort  The All of Us Research Program, part of the NIH, has awarded $4.6 million in initial funding to Color, a health technology company in Burlingame, California, to establish the program’s nationwide genetic counseling resource.
  August 21, 2019  
• Perrigo announces patent litigation settlement for generic version of Nascobal® spray  Perrigo announced that it has settled its Hatch-Waxman litigation relating to Nascobal® (Cyanocobalamin) Nasal Spray brought by Endo Pharmaceuticals. Terms of the settlement are confidential. Annual market sales for the 12-months ending June 2019 were $90 million as measured by IQVIA™.
  August 21, 2019  
• Cara Therapeutics enters into commercial license agreement with Enteris BioPharma  Cara Therapeutics announced a non-exclusive commercial license agreement with Enteris BioPharma for oral formulation rights to Enteris’ Peptelligence® Technology. Enteris will receive an upfront payment of $8 million, including $4 million in cash and $4 million in Cara common stock.
  August 21, 2019  
• Aimmune enrolls first patient in phase 2 trial of AR201 for egg allergy  Aimmune Therapeutics announced it has randomized its first patient in a phase 2 clinical trial of AR201 for treatment of egg allergy. AR201, an investigational biological drug for use in oral immunotherapy for egg allergy, is the second development program that Aimmune is advancing.
  August 21, 2019  
• Tonix Pharmaceuticals and Massachusetts General Hospital enter into research collaboration  Tonix Pharmaceuticals announced the signing of a research collaboration agreement with Massachusetts General Hospital, a teaching hospital of Harvard Medical School, to develop TNX-1500, a humanized monoclonal antibody that targets CD154 for prevention and treatment of organ transplant rejection.
  August 21, 2019  
• TGen and Ohio State collaborate on landmark precision medicine canine cancer study  like many women who develop a particular type of breast cancer, the same gene — HER2 — also appears to be the cause of lung cancer in many dogs, according to a promising new study of pet dogs led by TGen and The Ohio State University. The study was published in the journal Clinical Cancer Research.
  August 20, 2019  
• Study shows hunger-blocking hormone levels change with eating, obesity  Researchers at Southwestern and Imperial College London report the hormone LEAP2, which naturally blocks the “hunger” hormone ghrelin, is elevated in people with obesity, especially after eating – raising hopes for a treatment that could one day more effectively reduce appetite and, hence, obesity.
  August 20, 2019  
• Medtronic reports first quarter financial results  Medtronic reports first quarter worldwide revenue of $7.493 billion, an increase of 1.5 percent as reported or 3.5 percent on a constant currency basis. First quarter GAAP net income and diluted EPS were $864 million and $0.64, respectively.
  August 20, 2019  

   (next 10 articles)